Because genome editing technologies could reverse specific mutations and correct genetic defects responsible for cardiomyopathies, researchers looked at the clinical applications of genome editing in patients with heart failure, with family history, genetic predisposition to cardiomyopathies, exposure to cardiotoxic agents, and risk factors for heart failure considered.
Reference: Masarone D, Caiazza M, Amodio F, Melillo E, Pacileo R, Limongelli G, Pacileo G. Genome Editing and Heart Failure. Adv Exp Med Biol. 2023;1396:75-85. doi: 10.1007/978-981-19-5642-3_5. PMID: 36454460.
READ MORE > https://pubmed.ncbi.nlm.nih.gov/36454460/
